|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
ATE159982T1
(de)
|
1988-09-15 |
1997-11-15 |
Univ Columbia |
Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
|
|
JP2650358B2
(ja)
|
1988-10-06 |
1997-09-03 |
株式会社ニコン |
半透過部材を有する光学装置
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
CA2018248A1
(en)
|
1989-06-07 |
1990-12-07 |
Clyde W. Shearman |
Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
|
|
US5622929A
(en)
*
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
WO1994009817A1
(en)
|
1992-11-04 |
1994-05-11 |
City Of Hope |
Novel antibody construct
|
|
US5792456A
(en)
*
|
1994-08-04 |
1998-08-11 |
Bristol-Myers Squibb Company |
Mutant BR96 antibodies reactive with human carcinomas
|
|
EP0706799B1
(en)
|
1994-09-16 |
2001-11-14 |
MERCK PATENT GmbH |
Immunoconjugates II
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
WO1996040662A2
(en)
|
1995-06-07 |
1996-12-19 |
Cellpro, Incorporated |
Aminooxy-containing linker compounds and their application in conjugates
|
|
WO1997014719A1
(en)
|
1995-10-16 |
1997-04-24 |
Unilever N.V. |
A bifunctional or bivalent antibody fragment analogue
|
|
GB9524973D0
(en)
|
1995-12-06 |
1996-02-07 |
Lynxvale Ltd |
Viral vectors
|
|
SE9601245D0
(sv)
|
1996-03-29 |
1996-03-29 |
Pharmacia Ab |
Chimeric superantigens and their use
|
|
WO1997034632A1
(en)
*
|
1996-03-20 |
1997-09-25 |
Immunomedics, Inc. |
Glycosylated humanized b-cell specific antibodies
|
|
ATE386809T1
(de)
|
1996-08-02 |
2008-03-15 |
Bristol Myers Squibb Co |
Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
EP1028751B1
(en)
*
|
1997-10-31 |
2008-12-31 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
US6953675B2
(en)
*
|
1997-11-06 |
2005-10-11 |
Immunomedics, Inc. |
Landscaped antibodies and antibody fragments for clinical use
|
|
US6001817A
(en)
*
|
1998-01-12 |
1999-12-14 |
Unitech Pharmaceuticals, Inc. |
Pharmaceutical composition comprised of cisplatin, and processes for making and using same
|
|
EP1068241B1
(en)
|
1998-04-02 |
2007-10-10 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
WO2000009560A2
(en)
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
EP1115740A1
(en)
*
|
1998-09-23 |
2001-07-18 |
The Regents of the University of California |
Synthetic peptides, conjugation reagents and methods
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
|
US20020102208A1
(en)
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
|
CN1110322C
(zh)
*
|
1999-07-21 |
2003-06-04 |
中国医学科学院医药生物技术研究所 |
单克隆抗体Fab'－平阳霉素偶联物及其抗肿瘤作用
|
|
EP1294904A1
(en)
|
2000-06-30 |
2003-03-26 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
Heterodimeric fusion proteins
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
IL166244A0
(en)
|
2001-07-12 |
2006-01-15 |
Jefferson Foote |
Super humanized antibodies
|
|
US6900292B2
(en)
|
2001-08-17 |
2005-05-31 |
Lee-Hwei K. Sun |
Fc fusion proteins of human erythropoietin with increased biological activities
|
|
US7173003B2
(en)
*
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US7795210B2
(en)
*
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
|
US7214660B2
(en)
*
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7226903B2
(en)
*
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
|
US7265084B2
(en)
*
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
US7696163B2
(en)
*
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
ES2561985T3
(es)
|
2001-10-10 |
2016-03-01 |
Ratiopharm Gmbh |
Remodelación y glicoconjugación de anticuerpos
|
|
BR0213402A
(pt)
|
2001-10-29 |
2004-10-13 |
Crucell Holland Bv |
Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
JP2006502091A
(ja)
|
2002-03-01 |
2006-01-19 |
イミューノメディクス、インコーポレイテッド |
クリアランス速度を高めるための二重特異性抗体点変異
|
|
US7657380B2
(en)
|
2003-12-04 |
2010-02-02 |
Xencor, Inc. |
Methods of generating variant antibodies with increased host string content
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20070207142A1
(en)
*
|
2002-05-08 |
2007-09-06 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
ATE536188T1
(de)
|
2002-08-14 |
2011-12-15 |
Macrogenics Inc |
Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
|
|
EP1553975B8
(en)
|
2002-09-27 |
2023-04-12 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
EP1562972B1
(en)
|
2002-10-15 |
2010-09-08 |
Facet Biotech Corporation |
ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
|
|
ES2897506T3
(es)
|
2003-01-09 |
2022-03-01 |
Macrogenics Inc |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
|
|
EP2055189A1
(en)
*
|
2003-04-09 |
2009-05-06 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
UA87458C2
(ru)
|
2003-06-12 |
2009-07-27 |
Елі Ліллі Енд Компані |
Гибридные белки-аналоги glp-1
|
|
CN1871259A
(zh)
|
2003-08-22 |
2006-11-29 |
比奥根艾迪克Ma公司 |
具有改变的效应物功能的经改进的抗体和制备它的方法
|
|
RU2392324C2
(ru)
|
2003-09-18 |
2010-06-20 |
Симфоген А/С |
Способ связывания интересующих последовательностей
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
KR101520209B1
(ko)
|
2003-11-06 |
2015-05-13 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
|
US7001978B2
(en)
|
2003-11-19 |
2006-02-21 |
Xerox Corporation |
Unsaturated ester substituted polymers with reduced halogen content
|
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
CN101072789B
(zh)
*
|
2004-01-08 |
2013-05-15 |
生物种属学股份公司 |
肽的o-连接的糖基化
|
|
PL1706424T3
(pl)
|
2004-01-12 |
2010-04-30 |
Mentrik Biotech Llc |
Warianty regionu Fc
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
RU2006138181A
(ru)
*
|
2004-05-04 |
2008-06-10 |
Ново Нордиск Хелс Кеа Аг (Ch) |
О-связанные гликоформы полипептидов и способ их изготовления
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
CA2565961A1
(en)
|
2004-07-15 |
2006-02-23 |
Xencor, Inc. |
Optimized fc variants
|
|
CN101065151B
(zh)
*
|
2004-09-23 |
2014-12-10 |
健泰科生物技术公司 |
半胱氨酸改造的抗体和偶联物
|
|
JP2008537874A
(ja)
|
2004-09-27 |
2008-10-02 |
セントカー・インコーポレーテツド |
ｓＲＡＧＥミメティボディ、組成物、方法および使用
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
JP4829609B2
(ja)
|
2004-12-22 |
2011-12-07 |
独立行政法人科学技術振興機構 |
ヒト抗体酵素およびその生産方法
|
|
JP2008531764A
(ja)
|
2005-02-23 |
2008-08-14 |
リポクセン テクノロジーズ リミテッド |
タンパク質の誘導体化及び結合のための活性化シアル酸誘導体
|
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
|
EP1871808A2
(en)
|
2005-03-31 |
2008-01-02 |
Xencor, Inc. |
Fc VARIANTS WITH OPTIMIZED PROPERTIES
|
|
JP2008537941A
(ja)
*
|
2005-03-31 |
2008-10-02 |
ゼンコー・インコーポレイテッド |
最適化特性を有するＦｃ変異体
|
|
ES2523666T3
(es)
|
2005-05-31 |
2014-11-28 |
Board Of Regents, The University Of Texas System |
Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
|
|
AU2006261127B2
(en)
|
2005-06-17 |
2012-03-15 |
Merck Sharp & Dohme Corp. |
ILT3 binding molecules and uses therefor
|
|
CN101506238B
(zh)
|
2005-06-30 |
2013-11-06 |
森托科尔公司 |
具有提高治疗活性的方法和成分
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
|
SG175615A1
(en)
*
|
2006-06-06 |
2011-11-28 |
Genentech Inc |
Anti-dll4 antibodies and methods using same
|
|
EP2041180B8
(en)
|
2006-06-19 |
2014-03-05 |
Liquidating Trust |
Ilt3 binding molecules and uses therefor
|
|
US8580511B2
(en)
*
|
2006-06-19 |
2013-11-12 |
The Regents Of The University Of California |
Two-color fluorescent reporter for alternative pre-mRNA splicing
|
|
US7833260B2
(en)
|
2006-07-20 |
2010-11-16 |
Orbusneich Medical, Inc. |
Bioabsorbable polymeric medical device
|
|
US9187532B2
(en)
*
|
2006-07-21 |
2015-11-17 |
Novo Nordisk A/S |
Glycosylation of peptides via O-linked glycosylation sequences
|
|
MX2009003470A
(es)
|
2006-10-04 |
2009-04-14 |
Novo Nordisk As |
Azucares y glicopeptidos pegilados enlazados a glicerol.
|
|
FI20060946A0
(fi)
|
2006-10-26 |
2006-10-26 |
Glykos Finland Oy |
Influenssaviruksen nukleiinihappoja ja peptidejä
|
|
JP2010512306A
(ja)
*
|
2006-10-27 |
2010-04-22 |
ザ ロックフェラー ユニバーシティー |
抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
|
|
AR063975A1
(es)
|
2006-11-28 |
2009-03-04 |
Centelion |
Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
|
|
CA2674603C
(en)
|
2007-01-09 |
2016-03-29 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
|
JP5357778B2
(ja)
|
2007-01-23 |
2013-12-04 |
ゼンコー・インコーポレイテッド |
最適化ｃｄ４０抗体および前記を使用する方法
|
|
CL2008001334A1
(es)
|
2007-05-08 |
2008-09-22 |
Genentech Inc |
Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
|
|
WO2009045894A1
(en)
*
|
2007-09-28 |
2009-04-09 |
Centocor, Inc. |
Methods and structural conformations of antibody preparations with increased resistance to proteases
|
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
|
MX2010003718A
(es)
|
2007-10-19 |
2010-04-21 |
Genentech Inc |
Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
|
|
CA2711503A1
(en)
*
|
2008-01-08 |
2009-07-16 |
Biogenerix Ag |
Glycoconjugation of polypeptides using oligosaccharyltransferases
|
|
UA106586C2
(uk)
*
|
2008-01-31 |
2014-09-25 |
Дженентек, Інк. |
Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
|
|
US20110137011A1
(en)
|
2008-04-21 |
2011-06-09 |
Novo Nordisk A/S |
Hyperglycosylated human coagulation factor ix
|
|
UA40611U
(ru)
|
2008-05-26 |
2009-04-27 |
Владимир Семенович Живченко |
Способ десульфурации железоуглеродистого расплава в тигельной печи
|
|
JP2012501178A
(ja)
|
2008-08-26 |
2012-01-19 |
マクロジェニクス，インコーポレーテッド |
Ｔ細胞受容体抗体およびその使用方法
|
|
EP2233499A1
(en)
|
2009-03-26 |
2010-09-29 |
CSL Behring AG |
Antibody composition with altered Fab sialylation
|
|
US10087236B2
(en)
*
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
JP5826772B2
(ja)
|
2010-02-16 |
2015-12-02 |
ノヴォ ノルディスク アー／エス |
コンジュゲートタンパク質
|
|
EP2982380B1
(en)
|
2010-03-04 |
2021-09-01 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
BR112013003095B1
(pt)
*
|
2010-08-10 |
2023-03-28 |
Glycotope Gmbh |
Método para controle da meia-vida em circulação de um anticorpo ou um fragmento ou derivado funcional do mesmo, composições de anticorpo, seu usos e seus métodos de produção
|
|
AR085302A1
(es)
*
|
2011-02-24 |
2013-09-18 |
Sanofi Sa |
Metodo de produccion de anticuerpos sialilados
|
|
CN107088225A
(zh)
|
2011-03-11 |
2017-08-25 |
阿米库斯治疗学公司 |
治疗法布里病的给药方案
|
|
TWI838039B
(zh)
|
2011-03-28 |
2024-04-01 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
|
SG10201701831VA
(en)
|
2012-09-12 |
2017-05-30 |
Genzyme Corp |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
|
US9790268B2
(en)
*
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
|
WO2014164534A2
(en)
|
2013-03-11 |
2014-10-09 |
Genzyme Corporation |
Site-specific antibody-drug conjugation through glycoengineering
|
|
RS64072B1
(sr)
|
2014-03-19 |
2023-04-28 |
Genzyme Corp |
Mesto-specifični glikoinženjering ciljnih delova
|
|
CA2944539A1
(en)
|
2014-04-08 |
2015-10-15 |
University Of Georgia Research Foundation, Inc. |
Site-specific antibody-drug glycoconjugates and methods
|
|
PL3204425T3
(pl)
|
2014-10-09 |
2021-03-08 |
Genzyme Corporation |
Glikomodyfikowane koniugaty przeciwciał z lekami
|
|
CN113939534B
(zh)
|
2019-04-03 |
2025-02-28 |
建新公司 |
具有降低的断裂的抗αβTCR结合多肽
|